Impact of Interleukin-6 -174 G>C Gene Promoter Polymorphism on Neuroblastoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 9

PMID 24204677

Citations 13

Authors

Francesca Totaro

Flora Cimmino

Piero Pignataro

Giovanni Acierno

Marilena De Mariano

Luca Longo

Gian Paolo Tonini

Achille Iolascon

Mario Capasso

Affiliations

Soon will be listed here.

Abstract

Background: Common variants in DNA may predispose to onset and progression of neuroblastoma (NB). The genotype GG of single nucleotide polymorphism (SNP) rs1800795 (-174 G>C) in interleukin (IL)-6 promoter has been associated with lower survival of high-risk NB.

Result: To evaluate the impact of IL-6 SNP rs1800795 on disease risk and phenotype, we analyzed 326 Italian NB patients and 511 controls. Moreover, we performed in silico and quantitative Real Time (qRT)-PCR analyses to evaluate the influence of the SNP on gene expression in 198 lymphoblastoid cell lines (LCLs) and in 31 NB tumors, respectively. Kaplan-Meier analysis was used to verify the association between IL-6 gene expression and patient survival. We found that IL-6 SNP is not involved in susceptibility to NB development. However, our results show that a low frequency of genotype CC is significantly associated with a low overall survival, advanced stage, and high-risk phenotype. The in silico (p = 2.61 × 10(-5)) and qRT-PCR (p = 0.03) analyses showed similar trend indicating that the CC genotype is correlated with increased level of IL-6 expression. In report gene assay, we showed that the -174 C variant had a significantly increased transcriptional activity compared with G allele (p = 0.0006). Moreover, Kaplan-Meier analysis demonstrated that high levels of IL-6 are associated with poor outcome in children with NB in two independent gene expression array datasets.

Conclusions: The biological effect of SNP IL-6-174 G>C in relation to promotion of cancer progression is consistent with the observed decreased survival time. The present study suggests that SNP IL-6-174 G>C may be a useful marker for NB prognosis.

Citing Articles

Impacts of pro-inflammatory cytokines variant on cardiometabolic profile and premature coronary artery disease: A systematic review and meta-analysis.

Liu Y, Chen Y, Lin Y, Wei B, Luo Z J Cell Mol Med. 2024; 28(8):e18311.

PMID: 38634217 PMC: 11024509. DOI: 10.1111/jcmm.18311.

Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity.

Deng X, Tang K, Wang Z, He S, Luo Z J Epidemiol Glob Health. 2024; 14(2):363-378.

PMID: 38376765 PMC: 11176143. DOI: 10.1007/s44197-024-00204-w.

Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia.

Rostamzadeh Khameneh Z, Mohammadian M, Eishi Oskuie A, Asghari R, Nemati M Iran J Pathol. 2023; 18(4):392-397.

PMID: 38024543 PMC: 10646739. DOI: 10.30699/IJP.2023.544600.2790.

Beta-Lapachone Attenuates BMSC-Mediated Neuroblastoma Malignant Transformation by Inhibiting Gal-3/Gal-3BP/IL6 Axis.

Zhou Y, Yan H, Zhou Q, Feng R, Wang P, Yang F Front Pharmacol. 2021; 12:766909.

PMID: 34790130 PMC: 8591123. DOI: 10.3389/fphar.2021.766909.

Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk.

Harun-Or-Roshid M, Ali M, Jesmin , Haque Mollah M PLoS One. 2021; 16(3):e0247055.

PMID: 33684135 PMC: 7939379. DOI: 10.1371/journal.pone.0247055.

References

Egler R, Burlingame S, Nuchtern J, Russell H . Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res. 2008; 14(21):7028-34. PMC: 2613275. DOI: 10.1158/1078-0432.CCR-07-5017. View

Diskin S, Capasso M, Schnepp R, Cole K, Attiyeh E, Hou C . Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012; 44(10):1126-30. PMC: 3459292. DOI: 10.1038/ng.2387. View

Capasso M, Avvisati R, Piscopo C, Laforgia N, Raimondi F, de Angelis F . Cytokine gene polymorphisms in Italian preterm infants: association between interleukin-10 -1082 G/A polymorphism and respiratory distress syndrome. Pediatr Res. 2007; 61(3):313-7. DOI: 10.1203/pdr.0b013e318030d108. View

Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A . Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol. 2006; 14(2):329-39. DOI: 10.1245/s10434-006-9122-9. View

Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F . Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol. 2006; 33(4):703-8. View

Nica A, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M . The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 2011; 7(2):e1002003. PMC: 3033383. DOI: 10.1371/journal.pgen.1002003. View

Bosse K, Diskin S, Cole K, Wood A, Schnepp R, Norris G . Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012; 72(8):2068-78. PMC: 3328617. DOI: 10.1158/0008-5472.CAN-11-3703. View

Bruunsgaard H, Christiansen L, Pedersen A, Schroll M, Jorgensen T, Pedersen B . The IL-6 -174G>C polymorphism is associated with cardiovascular diseases and mortality in 80-year-old humans. Exp Gerontol. 2004; 39(2):255-61. DOI: 10.1016/j.exger.2003.10.012. View

Gimelbrant A, Hutchinson J, Thompson B, Chess A . Widespread monoallelic expression on human autosomes. Science. 2007; 318(5853):1136-40. DOI: 10.1126/science.1148910. View

10.

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner J, Attiyeh E . Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009; 41(6):718-23. PMC: 2753610. DOI: 10.1038/ng.374. View

11.

Capasso M, Diskin S, Totaro F, Longo L, De Mariano M, Russo R . Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2012; 34(3):605-11. PMC: 3716226. DOI: 10.1093/carcin/bgs380. View

12.

Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R . -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res. 2003; 9(6):2173-6. View

13.

Plagnol V, Uz E, Wallace C, Stevens H, Clayton D, Ozcelik T . Extreme clonality in lymphoblastoid cell lines with implications for allele specific expression analyses. PLoS One. 2008; 3(8):e2966. PMC: 2494943. DOI: 10.1371/journal.pone.0002966. View

14.

Jones K, Brull D, Brown L, Sian M, Greenhalgh R, Humphries S . Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation. 2001; 103(18):2260-5. DOI: 10.1161/01.cir.103.18.2260. View

15.

Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J . Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003; 63(13):3560-6. View

16.

Heikkila K, Ebrahim S, Lawlor D . Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008; 44(7):937-45. DOI: 10.1016/j.ejca.2008.02.047. View

17.

Ding J, Gudjonsson J, Liang L, Stuart P, Li Y, Chen W . Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals. Am J Hum Genet. 2010; 87(6):779-89. PMC: 2997368. DOI: 10.1016/j.ajhg.2010.10.024. View

18.

Maris J, Mosse Y, Bradfield J, Hou C, Monni S, Scott R . Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008; 358(24):2585-93. PMC: 2742373. DOI: 10.1056/NEJMoa0708698. View

19.

Terry C, Loukaci V, Green F . Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000; 275(24):18138-44. DOI: 10.1074/jbc.M000379200. View

20.

Chen M, Chen P, Lu M, Lin P, Chen W, Lee K . IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 2013; 12:26. PMC: 3667147. DOI: 10.1186/1476-4598-12-26. View